Translation expenses take center court in pharma legal battle
Written by ForeignExchange Translations on Sunday, June 21, 2009
Three-and-a-half years ago, Daiichi Pharma won a patent lawsuit against Mylan. Specifically, the US Court of Appeals for the Federal Circuit has affirmed the validity of Daiichi's U.S. patent no. 5,053,407 on levofloxacin, prohibiting Mylain from producing a generic version of levofloxacin until the expiration of Daiichi's patent.
Patent Baristas reported that in the aftermath to the lawsuit a tussle broke out over translation fees that Daiichi incurred and wanted Mylan to pay for.
And we're not talking a pittance here - $1.3 million in translation fees were at stake. The court's decision ensured that Daiichi wasn't "double-dipping" on it's cost recovery efforts. More details at the Patent Barista blog and in decision Ortho-McNeil Pharma v. Mylan Labs (08-1600) of the U.S. Court of Appeals for the Federal Circuit.
If this post made you wish you could sue somebody, subscribe to Medical Translation Blog via email or RSS.
